- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07544589
En fas 1-studie som utvärderar DISP-10 hos deltagare med avancerade gastrointestinala cancerformer
En fas 1-studie för att utvärdera säkerhet och effekt av DISP-10 hos deltagare med avancerade gastrointestinala cancrar
This is a Phase 1, multicenter, open-label study of DISP-10, a combination therapy consisting of DV-10 (adenovirus) and idecabtagene vicleucel (ide-cel, BCMA-directed chimeric antigen receptor [CAR] T), in adult participants with advanced gastrointestinal (GI) cancers.
The study will consist of 2 parts: dose-escalation (Part 1) and dose-expansion (Part 2). Part 1 of the study will evaluate the safety and tolerability of increasing dose levels of DISP-10 to establish the recommended dose for expansion (RDE); Part 2 will evaluate the safety and efficacy of DISP-10 in participants treated at the RDE.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 1
Kontakter och platser
Studiekontakt
- Namn: Dispatch Clinical
- Telefonnummer: (215) 792-4699
- E-post: clinicaltrials@dispatchbio.com
Studieorter
-
-
California
-
Duarte, California, Förenta staterna, 91010
- Rekrytering
- City of Hope
-
Newport Beach, California, Förenta staterna, 92663
- Rekrytering
- Hoag Memorial Hospital Presbyterian
-
-
Florida
-
Tampa, Florida, Förenta staterna, 33612
- Rekrytering
- Moffitt Cancer Center
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02215
- Rekrytering
- Dana-Farber Cancer Institute
-
-
Ohio
-
Cincinnati, Ohio, Förenta staterna, 45267
- Rekrytering
- University of Cincinnati Cancer Center
-
-
Tennessee
-
Nashville, Tennessee, Förenta staterna, 37203
- Har inte rekryterat ännu
- Tennessee Oncology
-
-
Utah
-
Salt Lake City, Utah, Förenta staterna, 84112
- Rekrytering
- Huntsman Cancer Institute
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Key Inclusion Criteria:
- Histologically confirmed advanced or metastatic esophageal, gastroesophageal junction, gastric adenocarcinoma, colorectal adenocarcinoma, or biliary tract carcinoma
- Measurable disease according to RECIST v1.1 and at least 1 additional site of disease amenable to biopsy
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- Aged ≥18 years at time of signing informed consent
- Adequate organ function
Key Exclusion Criteria:
- Previous solid organ or hematopoietic cell transplant
- Evidence of rapid disease progression, defined as radiographic or clinical progression within 3 months of the most recent prior line of therapy
- Known history of hepatitis B or HIV infection
- Previous or concurrent malignancy except if curatively treated more than 3 years prior to enrollment
- Known active central nervous system (CNS) metastases
- Clinically significant pleural or pericardial effusion or peritoneal carcinomatosis
- Active treatment with antiviral agents
- History of severe hypersensitivity to fludarabine or cyclophosphamide
- Prior therapies/treatments with oncolytic viruses or T cell derived cellular therapy
Additional criteria apply and should be discussed with the study site.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: DISP-10
Participants will receive DV-10 in combination with ide-cel. Lymphodepleting chemotherapy (fludarabine and cyclophosphamide) will be administered a few days prior to ide-cel. |
Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to produce ide-cel. During ide-cel production, participants may receive bridging therapy for disease control per Investigator discretion. DV-10 administration will be followed by lymphodepleting chemotherapy (fludarabine and cyclophosphamide) and subsequent ide-cel administration. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Incidence of Treatment Emergent Adverse Events (TEAEs)
Tidsram: 90 days (2 years for related Serious Adverse Events)
|
Graded using National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) v6.0 |
90 days (2 years for related Serious Adverse Events)
|
|
Incidence of Dose Limiting Toxicities (DLTs) [PART 1]
Tidsram: 28 days
|
Graded using National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) v6.0 |
28 days
|
|
Identification of the Recommended Dose for Expansion (RDE) [PART 1]
Tidsram: Up to 2 years
|
To select the Recommended Dose for Expansion (RDE) for Part 2 |
Up to 2 years
|
|
Overall response rate (ORR) [PART 2]
Tidsram: Up to 2 years
|
Confirmed complete response (CR) or partial response (PR), per RECIST v1.1 |
Up to 2 years
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Overall response rate (ORR) [PART 1]
Tidsram: Up to 2 years
|
Confirmed CR or PR, per RECIST v1.1 |
Up to 2 years
|
|
Disease control rate (DCR)
Tidsram: Up to 2 years
|
Proportion of participants with CR, PR, or stable disease per RECIST v1.1 |
Up to 2 years
|
|
Duration of response (DOR)
Tidsram: Up to 2 years
|
Time from CR or PR to radiographic progression or death |
Up to 2 years
|
|
Progression Free Survival (PFS)
Tidsram: Up to 2 years
|
Time from ide-cel administration to disease progression or death, whichever occurs first |
Up to 2 years
|
|
Overall survival (OS)
Tidsram: Up to 15 years
|
Time from ide-cel administration to death |
Up to 15 years
|
|
Time to response (TTR)
Tidsram: Up to 2 years
|
Time from ide-cel administration to the first documentation of objective tumor response |
Up to 2 years
|
|
Cellular kinetics (CK) of ide-cel
Tidsram: Up to 2 years
|
Measurement of ide-cel CK in the blood |
Up to 2 years
|
|
Pharmacokinetics of DV-10 - Cmax
Tidsram: Up to 2 years
|
Maximum concentration in blood |
Up to 2 years
|
|
Pharmacokinetics of DV-10 - Tmax
Tidsram: Up to 2 years
|
Time to maximum concentration in blood |
Up to 2 years
|
|
Pharmacokinetics of DV-10 - AUC
Tidsram: Up to 2 years
|
Area under the blood concentration curve |
Up to 2 years
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Neoplasmer efter plats
- Neoplasmer
- Tarmsjukdomar
- Infektioner
- Virussjukdomar
- Neoplasmer i matsmältningssystemet
- Matsmältningssystemets sjukdomar
- Gastrointestinala sjukdomar
- Intestinala neoplasmer
- Rektala sjukdomar
- Kolonsjukdomar
- DNA-virusinfektioner
- Kolorektala neoplasmer
- Gastrointestinala neoplasmer
- Adenoviridae-infektioner
- Adenocarcinom i matstrupen
Andra studie-ID-nummer
- DISP-10-101
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .